Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in TRAPS
NCT01242813Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Jun 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of canakinumab in TNF receptor-associated periodic syndrome (TRAPS), sponsored by Novartis. Started Oct 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
TNF receptor-associated periodic syndrome (TRAPS)
Beyond the preview
Go deeper on NCT01242813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242813.